Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function". It is through the use of innovative medical means rebuilding diseased or damaged tissue or to support diseased or damaged tissue regeneration. The methods used include cell therapy, tissue engineering, chemically induced and therapeutic cloning, etc. Any combination of these technologies may be used to harness or stimulate the body鈥檚 innate healing ability in order to treat a wide range of ailments, including musculoskeletal-related conditions, cardio- and peripheral vascular diseases, neurological disorders, stroke, non-healing wounds and ocular diseases.
Regenerative medicine is defined as the process of replacing or "regenerating" human cells, tissues or organs to restore or establish normal function and has been called the "next evolution of medical treatments" and 鈥渢he vanguard of 21st century healthcare鈥� by the U.S. Department of Health and Human Services.
麻豆原创 Analysis and Insights: Global Regenerative Medicine 麻豆原创
The global Regenerative Medicine market is projected to grow from US$ 40320 million in 2024 to US$ 115660 million by 2030, at a Compound Annual Growth Rate (CAGR) of 19.2% during the forecast period.
Global Regenerative Medicine key players include J & J (DePuy Synthes), Medtronic, Allergan(Acelity), Zimmer Biomet, etc. Global top four manufacturers hold a share about 10%.
North America is the largest market, with a share about 25%, followed by Europe, and Asia Pacific, both have a share over 40 percent.
In terms of product, Tissue Engineering is the largest segment, with a share over 40%. And in terms of application, the largest application is Dermatology, followed by Cardiovascular, CNS, Orthopedic, etc.
Report Covers:
This report presents an overview of global market for Regenerative Medicine market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Regenerative Medicine, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Regenerative Medicine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Regenerative Medicine revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Regenerative Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Regenerative Medicine revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
J & J (DePuy Synthes)
Medtronic
Zimmer Biomet
Stryker
Allergan(Acelity)
MiMedx Group
Organogenesis
Fujifilm Cellular Dynamics
Osiris Therapeutics
Vcanbio
CCBC
Cytori
Celgene
Vericel Corporation
Guanhao Biotech
Mesoblast
AMAG Pharmaceuticals (CBR)
ViaCord
CordLife
Integra LifeSciences
Nuvasive
Cook Biotech
Japan Tissue Engineering
Segment by Type
Cell Therapy
Tissue Engineering
Biomaterial
Other
Segment by Application
Dermatology
Cardiovascular
CNS
Orthopedic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Regenerative Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Regenerative Medicine companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Regenerative Medicine revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Regenerative Medicine 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Cell Therapy
1.2.3 Tissue Engineering
1.2.4 Biomaterial
1.2.5 Other
1.3 麻豆原创 by Application
1.3.1 Global Regenerative Medicine 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Dermatology
1.3.3 Cardiovascular
1.3.4 CNS
1.3.5 Orthopedic
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Regenerative Medicine 麻豆原创 Perspective (2019-2030)
2.2 Global Regenerative Medicine Growth Trends by Region
2.2.1 Regenerative Medicine 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Regenerative Medicine Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Regenerative Medicine Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Regenerative Medicine 麻豆原创 Dynamics
2.3.1 Regenerative Medicine Industry Trends
2.3.2 Regenerative Medicine 麻豆原创 Drivers
2.3.3 Regenerative Medicine 麻豆原创 Challenges
2.3.4 Regenerative Medicine 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Regenerative Medicine by Players
3.1.1 Global Regenerative Medicine Revenue by Players (2019-2024)
3.1.2 Global Regenerative Medicine Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Regenerative Medicine 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Regenerative Medicine, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Regenerative Medicine 麻豆原创 Concentration Ratio
3.4.1 Global Regenerative Medicine 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Regenerative Medicine Revenue in 2023
3.5 Global Key Players of Regenerative Medicine Head office and Area Served
3.6 Global Key Players of Regenerative Medicine, Product and Application
3.7 Global Key Players of Regenerative Medicine, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Regenerative Medicine Breakdown Data by Type
4.1 Global Regenerative Medicine Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Regenerative Medicine Forecasted 麻豆原创 Size by Type (2025-2030)
5 Regenerative Medicine Breakdown Data by Application
5.1 Global Regenerative Medicine Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Regenerative Medicine Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Regenerative Medicine 麻豆原创 Size (2019-2030)
6.2 North America Regenerative Medicine 麻豆原创 Size by Type
6.2.1 North America Regenerative Medicine 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Regenerative Medicine 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Regenerative Medicine 麻豆原创 Share by Type (2019-2030)
6.3 North America Regenerative Medicine 麻豆原创 Size by Application
6.3.1 North America Regenerative Medicine 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Regenerative Medicine 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Regenerative Medicine 麻豆原创 Share by Application (2019-2030)
6.4 North America Regenerative Medicine 麻豆原创 Size by Country
6.4.1 North America Regenerative Medicine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Regenerative Medicine 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Regenerative Medicine 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Regenerative Medicine 麻豆原创 Size (2019-2030)
7.2 Europe Regenerative Medicine 麻豆原创 Size by Type
7.2.1 Europe Regenerative Medicine 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Regenerative Medicine 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Regenerative Medicine 麻豆原创 Share by Type (2019-2030)
7.3 Europe Regenerative Medicine 麻豆原创 Size by Application
7.3.1 Europe Regenerative Medicine 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Regenerative Medicine 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Regenerative Medicine 麻豆原创 Share by Application (2019-2030)
7.4 Europe Regenerative Medicine 麻豆原创 Size by Country
7.4.1 Europe Regenerative Medicine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Regenerative Medicine 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Regenerative Medicine 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Regenerative Medicine 麻豆原创 Size (2019-2030)
8.2 China Regenerative Medicine 麻豆原创 Size by Type
8.2.1 China Regenerative Medicine 麻豆原创 Size by Type (2019-2024)
8.2.2 China Regenerative Medicine 麻豆原创 Size by Type (2025-2030)
8.2.3 China Regenerative Medicine 麻豆原创 Share by Type (2019-2030)
8.3 China Regenerative Medicine 麻豆原创 Size by Application
8.3.1 China Regenerative Medicine 麻豆原创 Size by Application (2019-2024)
8.3.2 China Regenerative Medicine 麻豆原创 Size by Application (2025-2030)
8.3.3 China Regenerative Medicine 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Regenerative Medicine 麻豆原创 Size (2019-2030)
9.2 Asia Regenerative Medicine 麻豆原创 Size by Type
9.2.1 Asia Regenerative Medicine 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Regenerative Medicine 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Regenerative Medicine 麻豆原创 Share by Type (2019-2030)
9.3 Asia Regenerative Medicine 麻豆原创 Size by Application
9.3.1 Asia Regenerative Medicine 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Regenerative Medicine 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Regenerative Medicine 麻豆原创 Share by Application (2019-2030)
9.4 Asia Regenerative Medicine 麻豆原创 Size by Region
9.4.1 Asia Regenerative Medicine 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Regenerative Medicine 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Regenerative Medicine 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Regenerative Medicine 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 J & J (DePuy Synthes)
11.1.1 J & J (DePuy Synthes) Company Details
11.1.2 J & J (DePuy Synthes) Business Overview
11.1.3 J & J (DePuy Synthes) Regenerative Medicine Introduction
11.1.4 J & J (DePuy Synthes) Revenue in Regenerative Medicine Business (2019-2024)
11.1.5 J & J (DePuy Synthes) Recent Developments
11.2 Medtronic
11.2.1 Medtronic Company Details
11.2.2 Medtronic Business Overview
11.2.3 Medtronic Regenerative Medicine Introduction
11.2.4 Medtronic Revenue in Regenerative Medicine Business (2019-2024)
11.2.5 Medtronic Recent Developments
11.3 Zimmer Biomet
11.3.1 Zimmer Biomet Company Details
11.3.2 Zimmer Biomet Business Overview
11.3.3 Zimmer Biomet Regenerative Medicine Introduction
11.3.4 Zimmer Biomet Revenue in Regenerative Medicine Business (2019-2024)
11.3.5 Zimmer Biomet Recent Developments
11.4 Stryker
11.4.1 Stryker Company Details
11.4.2 Stryker Business Overview
11.4.3 Stryker Regenerative Medicine Introduction
11.4.4 Stryker Revenue in Regenerative Medicine Business (2019-2024)
11.4.5 Stryker Recent Developments
11.5 Allergan(Acelity)
11.5.1 Allergan(Acelity) Company Details
11.5.2 Allergan(Acelity) Business Overview
11.5.3 Allergan(Acelity) Regenerative Medicine Introduction
11.5.4 Allergan(Acelity) Revenue in Regenerative Medicine Business (2019-2024)
11.5.5 Allergan(Acelity) Recent Developments
11.6 MiMedx Group
11.6.1 MiMedx Group Company Details
11.6.2 MiMedx Group Business Overview
11.6.3 MiMedx Group Regenerative Medicine Introduction
11.6.4 MiMedx Group Revenue in Regenerative Medicine Business (2019-2024)
11.6.5 MiMedx Group Recent Developments
11.7 Organogenesis
11.7.1 Organogenesis Company Details
11.7.2 Organogenesis Business Overview
11.7.3 Organogenesis Regenerative Medicine Introduction
11.7.4 Organogenesis Revenue in Regenerative Medicine Business (2019-2024)
11.7.5 Organogenesis Recent Developments
11.8 Fujifilm Cellular Dynamics
11.8.1 Fujifilm Cellular Dynamics Company Details
11.8.2 Fujifilm Cellular Dynamics Business Overview
11.8.3 Fujifilm Cellular Dynamics Regenerative Medicine Introduction
11.8.4 Fujifilm Cellular Dynamics Revenue in Regenerative Medicine Business (2019-2024)
11.8.5 Fujifilm Cellular Dynamics Recent Developments
11.9 Osiris Therapeutics
11.9.1 Osiris Therapeutics Company Details
11.9.2 Osiris Therapeutics Business Overview
11.9.3 Osiris Therapeutics Regenerative Medicine Introduction
11.9.4 Osiris Therapeutics Revenue in Regenerative Medicine Business (2019-2024)
11.9.5 Osiris Therapeutics Recent Developments
11.10 Vcanbio
11.10.1 Vcanbio Company Details
11.10.2 Vcanbio Business Overview
11.10.3 Vcanbio Regenerative Medicine Introduction
11.10.4 Vcanbio Revenue in Regenerative Medicine Business (2019-2024)
11.10.5 Vcanbio Recent Developments
11.11 CCBC
11.11.1 CCBC Company Details
11.11.2 CCBC Business Overview
11.11.3 CCBC Regenerative Medicine Introduction
11.11.4 CCBC Revenue in Regenerative Medicine Business (2019-2024)
11.11.5 CCBC Recent Developments
11.12 Cytori
11.12.1 Cytori Company Details
11.12.2 Cytori Business Overview
11.12.3 Cytori Regenerative Medicine Introduction
11.12.4 Cytori Revenue in Regenerative Medicine Business (2019-2024)
11.12.5 Cytori Recent Developments
11.13 Celgene
11.13.1 Celgene Company Details
11.13.2 Celgene Business Overview
11.13.3 Celgene Regenerative Medicine Introduction
11.13.4 Celgene Revenue in Regenerative Medicine Business (2019-2024)
11.13.5 Celgene Recent Developments
11.14 Vericel Corporation
11.14.1 Vericel Corporation Company Details
11.14.2 Vericel Corporation Business Overview
11.14.3 Vericel Corporation Regenerative Medicine Introduction
11.14.4 Vericel Corporation Revenue in Regenerative Medicine Business (2019-2024)
11.14.5 Vericel Corporation Recent Developments
11.15 Guanhao Biotech
11.15.1 Guanhao Biotech Company Details
11.15.2 Guanhao Biotech Business Overview
11.15.3 Guanhao Biotech Regenerative Medicine Introduction
11.15.4 Guanhao Biotech Revenue in Regenerative Medicine Business (2019-2024)
11.15.5 Guanhao Biotech Recent Developments
11.16 Mesoblast
11.16.1 Mesoblast Company Details
11.16.2 Mesoblast Business Overview
11.16.3 Mesoblast Regenerative Medicine Introduction
11.16.4 Mesoblast Revenue in Regenerative Medicine Business (2019-2024)
11.16.5 Mesoblast Recent Developments
11.17 AMAG Pharmaceuticals (CBR)
11.17.1 AMAG Pharmaceuticals (CBR) Company Details
11.17.2 AMAG Pharmaceuticals (CBR) Business Overview
11.17.3 AMAG Pharmaceuticals (CBR) Regenerative Medicine Introduction
11.17.4 AMAG Pharmaceuticals (CBR) Revenue in Regenerative Medicine Business (2019-2024)
11.17.5 AMAG Pharmaceuticals (CBR) Recent Developments
11.18 ViaCord
11.18.1 ViaCord Company Details
11.18.2 ViaCord Business Overview
11.18.3 ViaCord Regenerative Medicine Introduction
11.18.4 ViaCord Revenue in Regenerative Medicine Business (2019-2024)
11.18.5 ViaCord Recent Developments
11.19 CordLife
11.19.1 CordLife Company Details
11.19.2 CordLife Business Overview
11.19.3 CordLife Regenerative Medicine Introduction
11.19.4 CordLife Revenue in Regenerative Medicine Business (2019-2024)
11.19.5 CordLife Recent Developments
11.20 Integra LifeSciences
11.20.1 Integra LifeSciences Company Details
11.20.2 Integra LifeSciences Business Overview
11.20.3 Integra LifeSciences Regenerative Medicine Introduction
11.20.4 Integra LifeSciences Revenue in Regenerative Medicine Business (2019-2024)
11.20.5 Integra LifeSciences Recent Developments
11.21 Nuvasive
11.21.1 Nuvasive Company Details
11.21.2 Nuvasive Business Overview
11.21.3 Nuvasive Regenerative Medicine Introduction
11.21.4 Nuvasive Revenue in Regenerative Medicine Business (2019-2024)
11.21.5 Nuvasive Recent Developments
11.22 Cook Biotech
11.22.1 Cook Biotech Company Details
11.22.2 Cook Biotech Business Overview
11.22.3 Cook Biotech Regenerative Medicine Introduction
11.22.4 Cook Biotech Revenue in Regenerative Medicine Business (2019-2024)
11.22.5 Cook Biotech Recent Developments
11.23 Japan Tissue Engineering
11.23.1 Japan Tissue Engineering Company Details
11.23.2 Japan Tissue Engineering Business Overview
11.23.3 Japan Tissue Engineering Regenerative Medicine Introduction
11.23.4 Japan Tissue Engineering Revenue in Regenerative Medicine Business (2019-2024)
11.23.5 Japan Tissue Engineering Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
J & J (DePuy Synthes)
Medtronic
Zimmer Biomet
Stryker
Allergan(Acelity)
MiMedx Group
Organogenesis
Fujifilm Cellular Dynamics
Osiris Therapeutics
Vcanbio
CCBC
Cytori
Celgene
Vericel Corporation
Guanhao Biotech
Mesoblast
AMAG Pharmaceuticals (CBR)
ViaCord
CordLife
Integra LifeSciences
Nuvasive
Cook Biotech
Japan Tissue Engineering
听
听
*If Applicable.
